COVID-19 associated pulmonary aspergillosis: a nationwide survey by the Japanese Respiratory Society
- 1Department of Respiratory Medicine, Nagasaki University Hospital, Nagasaki, Japan
- 2Department of Infectious Diseases, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
- 3Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
- 4Department for Infectious Diseases, Keio University School of Medicine, Tokyo, Japan
- 5Department of Respiratory and Allergology Medicine, Kochi Medical School, Kochi University, Kochi, Japan
- Takahiro Takazono (takahiro-takazono{at}nagasaki-u.ac.jp)
Footnotes
This manuscript has recently been accepted for publication in the ERJ Open Research. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJOR online. Please open or download the PDF to view this article.
Conflict of interest: Dr. Takahiro Takazono reports grants and personal fees from MSD Co., Ltd., personal fees from Pfizer Inc., grants and personal fees from Sumitomo Dainippon Pharma Co., Ltd., grants from Shionogi Inc., outside the submitted work.
Conflict of interest: Dr. Hiroshi Mukae reports personal fees from AbbVie GK, grants and personal fees from Asahi Kasei Pharma Corporation, grants and personal fees from Astellas Pharma Inc., personal fees from AstraZeneca K.K., personal fees from Bristol-Myers Squibb, personal fees from Eli Lilly Japan K.K., grants and personal fees from FUJIFILM Toyama Chemical Co., Ltd., personal fees from Gilead Sciences Inc., personal fees from Insmed Incorporated, personal fees from Janssen Pharmaceutical K.K., grants and personal fees from Kyorin Pharmaceutical Co., Ltd., grants and personal fees from Meiji Seika Pharma Co., Ltd., personal fees from Mitsubishi Tanabe Pharma Corporation, personal fees from MSD Co., Ltd., personal fees from Nihon Pharmaceutical Co., Ltd., personal fees from Nippon Boehringer Ingelheim Co ., Ltd., personal fees from Novartis Pharma K.K, grants and personal fees from Pfizer Inc., personal fees from Sumitomo Dainippon Pharma Co., Ltd., grants and personal fees from Taiho Pharmaceutical Co., Ltd., grants and personal fees from Taisho Pharma Co., Ltd, personal fees from Teijin Home Healthcare Limited., grants from Teijin Pharma Limited, grants and personal fees from Toa Shinyaku Co., Ltd., grants from Torii Pharmaceutical Co.,Ltd, grants from Shionogi Inc., outside the submitted work; .
Conflict of interest: Dr. Koichi Izumikawa has nothing to disclose.
Conflict of interest: Dr. Naoki Hasegawa has nothing to disclose.
Conflict of interest: Dr. Akihito Yokoyama reports personal fees from AstraZeneca, personal fees from Boehrlnger Ingelheim, personal fees from Novartis, personal fees from GlaxoSmithKlein, personal fees from Sanofi, outside the submitted work; .
This is a PDF-only article. Please click on the PDF link above to read it.
- Received June 17, 2021.
- Accepted August 17, 2021.
- Copyright ©The authors 2021
This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions{at}ersnet.org